José Falantes

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym et al. · Blood · 2015 · 1.1K citations · Full text

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

Manuela Aguilar‐Guisado, Ildefonso Espigado, Almudena Martín‐Peña et al. · The Lancet Haematology · 2017 · 230 citations

Antibiotics, Antimicrobial Stewardship, Phase 4 +9

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Guillermo Garcia‐Manero, Valeria Santini, António Almeida et al. · Journal of Clinical Oncology · 2021 · 75 citations · Full text

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

John F. Seymour, Hartmut Döhner, Aleksandra Butrym et al. · BMC Cancer · 2017 · 71 citations · Full text